Rockwell Medical, Inc. (RMTI) AI Stock Analysis

Rockwell Medical, Inc. is a biopharmaceutical company specializing in therapies and products for patients with end-stage renal disease and chronic kidney disease across the United States and internationally. Its central offerings include Triferic Dialysate and Triferic AVNU, iron therapies engineered to replenish iron and maintain hemoglobin levels in dialysis patients without increasing iron stores. Rockwell Medical also manufactures, sells, and distributes hemodialysis concentrates, including CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, and RenalPure liquid acid concentrate. Additionally, the company is actively developing therapeutic candidates for acute heart failure management and home infusion therapy.

Rockwell Medical grew annual revenue from $61.9M in FY2021 to $101.5M in FY2024, before revenue dropped 31.8% to $69.3M in FY2025. Gross margin expanded from -3.9% in FY2021 to 17.2% in FY2024 and stood at 16.9% in FY2025. Operating margin improved from -49.0% in FY2021 to 0.6% in FY2024, returning to -6.8% in FY2025. Annual net losses shrank from -$32.7M in FY2021 to -$480,000 in FY2024, followed by a loss of -$5.3M in FY2025. Over the trailing twelve months, revenue reached $69.4M with an operating margin of -6.0%. For the latest quarter ended June 30, 2026, quarterly revenue growth accelerated 10.6% year-over-year.

As of June 30, 2026, Rockwell Medical held $24.8M in cash and short-term investments and $13.9M in total debt, resulting in net cash of $10.9M. Total assets stood at $56.5M against shareholders' equity of $35.1M, supporting a current ratio of 3.25 and a debt-to-equity ratio of 0.40. In FY2025, operating cash flow was -$659,000, free cash flow was -$1.2M, and capital expenditures were $542,000. Over five years, its share count changed by -95.8%.

Rockwell Medical trades at an enterprise value of $24.8M and a market capitalization of $29.9M. Its forward P/E ratio is 24.6x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales multiple is 0.4x, well below the peer median of 4.1x, while EV-to-EBITDA stands at 30.2x versus the peer median of 12.0x. Over the past year, the stock dropped 37.6%, lagging the 16.8% return for the S&P 500 (SPY). Over five years, the stock fell 88.7% while the S&P 500 gained 83.0%.

Wall Street coverage includes 1 Strong Buy, 1 Buy, 0 Holds, and 0 Sells. The mean price target is $20.00, representing a 169.2% premium over the last close of $7.43. For the current fiscal year ending December 31, 2026, consensus estimates project an EPS of -$1.01 on revenue of $72.3M. For the next fiscal year, 2 analysts project an EPS of -$0.20 and revenue of $78.2M, representing 8.0% revenue growth. Rockwell Medical beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 12, 2026.

This page is an AI-written research summary of Rockwell Medical, Inc. (RMTI). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RMTI income statement, RMTI balance sheet, RMTI key metrics, RMTI analyst forecast, RMTI chart. See the RMTI stock overview for the latest quote and news.